Dr. Graham Timmins Engaged by TenthGate

New York, New York, UNITED STATES

RESTON, Va., Sept. 24, 2007 (PRIME NEWSWIRE) -- TenthGate International, Inc. (Pink Sheets:TGTI) www.TenthGate.biz ("TenthGate"), an innovative medical holding company focusing on healthcare related life-changing technologies, has entered a technical consulting agreement with Dr. Graham Timmins in support of the company's licensed Melanocyte Protective Factor (MPF) sunscreen diagnostics technologies commercialization initiatives utilizing Electron Paramagnetic Resonance (EPR).

Dr. Timmins is retained as a consultant for the following services:

 -- Strategic and technical support for MPF commercialization.

 -- Technical support for future communication with the FDA on MPF.

 -- Technical support working with EPR equipment manufacturer for
    R & D support for MPF commercialization.

 -- Technical oversight for work related to required FDA approvals on
    technologies associated with MPF.

TenthGate has acquired a suite of technology licenses from STC.UNM (http://stc.unm.edu/) that were developed at the University of New Mexico School of Pharmacy by Dr. Graham Timmins. Dr. Timmins' research and technology patents focus on understanding specific causation factors of melanoma skin cancer, using Electron Paramagnetic Resonance (EPR) as the diagnostics medium at the cellular level.

Dr. Graham Timmins is a University of New Mexico professor of medicinal chemistry and toxicology who has developed the Melanoscan. The device uses "Electron Paramagnetic Resonance" (EPR) or magnetic waves to detect cancerous or precancerous moles on the human body. Dr. Timmins is a recipient of a National Institute of Health (NIH) grant related to his EPR melanoma research and methodologies validations.

"It's like a small MRI machine to measure free radicals that affect melanin, or pigment, in skin," Timmins says. "Optical, or light-based, devices can only get about one-tenth of an inch into the skin, which is not enough to image melanoma. We can go much deeper to actually measure and image the free radicals that mutate the cells." And, by measuring the level of free radicals in cells, the technology can set a new standard for determining how effective sunscreens and other cosmetics are in protecting against ultra-violet rays."

About Dr. Graham Timmins


TenthGate looks to provide sunscreen manufacturers and retailers a more exact description of the UVA/UVB protective qualities of sunscreens and other cosmetic products as well as assisting in the development of new, more effective formulations. This technology serves to provide consumers more accurate information with which to make better informed decisions on responsible sun exposure protective measures.

Description of TenthGate's EPR Technology Applications:


About TenthGate

TenthGate International, Inc. is focused on the acquisition and development of life changing, health related technologies. The range of acquired technologies includes biotech/life sciences, diagnostic, and unique medical devices. The Company has acquired several intellectual properties and licenses to date, two of which have obtained FDA approval. The company has obtained exclusive license for an emerging melanoma diagnostic and prevention technology utilizing Electron Paramagnetic Resonance (EPR) technology. TenthGate has identified several additional technologies for acquisition.

The TenthGate International, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3179

Safe Harbor Disclaimer

Except for the historical information contained herein, the matters discussed in this press release may include forward-looking statements or information. All statements, other than statements of historical fact, including, without limitation, those with respect to the objectives, plans and strategies of TenthGate International, Inc., and its affiliates, set forth herein and those preceded by or that include the words "believes," "expects," "given," "targets," "intends," "anticipates," "plans," "projects", "forecasts" or similar expressions, are forward-looking statements. Although the Company's management believes that such forward-looking statements are reasonable, it cannot guarantee that such expectations are, or will be, correct. These forward-looking statements involve a number of risks and uncertainties which could cause the Company's future results to differ materially from those anticipated. The Company assumes no obligation to update any of the information contained or referenced in this press release.


Contact Data